Laplace Interventional Secures $22M Series C Financing for User-Friendly Transcatheter Tricuspid Valve Replacement System

Laplace InterventionalAnnounced the completion of a $22 million Series C financing round, led by an undisclosed global strategic investor, with participation from Aphelion Capital, Engage Venture Partners, Unorthodox Ventures, JWC Ventures, and Features Capital.

Investor Evaluation

"As a venture capital fund dedicated to investing in innovative medical products, services, and technologies that align with the mission of the American Heart Association, Aphelion Cardeation is honored to participate in this round of financing. Laplace Interventional's innovative solutions for TR and their potential to transform the treatment paradigm for millions of patients worldwide are truly inspiring."

---Ned Scheetz  Representative of Aphelion Capital

Executive Evaluation

"This round of financing marks an important milestone in the company's development, fully validating the progress achieved over the past few years. We sincerely thank patients, clinical experts, and both new and existing investors for their continued support, and we look forward to advancing the launch of pivotal clinical trials. The proceeds from this round will be used to complete feasibility studies in the U.S. and overseas, and to prepare for pivotal studies."

---Ramji Iyer  Founder and CEO of Laplace Interventional

Laplace InterventionalIs currently developing its TTVR productLaplaceOfEarly Feasibility Study (EFS). CurrentlyIn the United States, 22 patients have been enrolled (out of 25 globally), all included in the U.S. EFS study, with preliminary results being positive.

PI Evaluation

"We have completed the treatment of three patients in the Laplace Early Feasibility Study (EFS). All patients were discharged within 1-2 days post-operation and are recovering well. This is our first experience with a dedicated transcatheter tricuspid valve replacement platform, and we are impressed by Laplace’s intuitive deployment process, imaging compatibility, and overall ease of use in complex anatomical structures."

---Brandon Jones St. Vincent Medical Center

Tricuspid Regurgitation (TR) refers to the abnormal backflow of blood caused by incomplete closure of the tricuspid valve. During the progression of functional TR, the tricuspid annulus, originally a saddle-shaped ellipsoid, gradually flattens and becomes circular as it dilates. Patients with TR may experience fatigue, reduced exercise tolerance, limb swelling, arrhythmias, and shortness of breath, ultimately leading to right-sided heart failure and cardiogenic cirrhosis.

Current TreatmentTricuspid regurgitation technology is increasing. In addition to surgical replacement and repair, transcatheter replacement and repair technologies have recently been gradually approved for marketing by drug regulatory authorities in various countries. Among them,Transcatheter replacement technology, Edwards' EVOQUE received FDA approval for market launch last year. CurrentlyEVOQUE is the only approved product on the marketTranscatheter replacement technology, but due toA large patient population with tricuspid regurgitation and significant variations in patient anatomy, among other reasons, present challenges for innovation.There is still a huge demand for transcatheter replacement technology.Laplace InterventionalOpenedTranscatheter Replacement TechnologyLaplaceIt is a very promising technology and a potential acquisition target for major companies in the future.

Laplace

LaplaceIt is an innovative and very easy-to-use TTVR.Laplace Interventional SummarizedLaplaceThree Advantages:

• Easy to Operate

26F transjugular approach design, featuring both imaging compatibility and high controllability (supports valve repositioning and full retrieval).

• Universal Design

Unique Valve Structure Adapts to Complex Anatomy: Compatible with Large Annulus Sizes; Avoids Interference from Adjacent Ventricular Structures (Moderator Band, Papillary Muscles Near the Tricuspid Annulus); Effectively Addresses Various Native Leaflet Abnormalities (Fused Leaflets, Leaflet Defects, Carcinoid Heart Disease, etc.).

• Gentle Fit

Flexible Stent Design to Protect Native Anatomy: Tissue-to-tissue interface at the atrioventricular node contact surface; dedicated channel for future pacemaker leads.

Laplace Demonstration

Laplace Interventional

Laplace InterventionalLaplace Interventional, Inc. is an innovative medical device company dedicated to improving the quality of life for patients with tricuspid regurgitation (TR) worldwide through its innovative devices. The prosthetic valve under development can be implanted via minimally invasive surgery, eliminating the need for open-heart surgery, thereby reducing the risk of postoperative complications for patients.